AVADEL PHARMACEUTICALS-ADR logo

AVDL

AVADEL PHARMACEUTICALS-ADR

$9.19

Earnings Summary

Q3 FY2022-2023Q2 FY2022-2023Q1 FY2022-2023Q4 FY2021-2022Q3 FY2021-2022Q2 FY2021-2022Q1 FY2021-2022Q4 FY2020-2021Q3 FY2020-2021Q2 FY2020-2021Q1 FY2020-2021Q4 FY2019-2020Q3 FY2019-2020Q2 FY2019-2020Q1 FY2019-2020Q4 FY2018-2019Q3 FY2018-2019Q2 FY2018-2019Q1 FY2018-2019Q4 FY2017-2018Q3 FY2017-2018Q2 FY2017-2018Q1 FY2017-2018Q4 FY2016-2017Q3 FY2016-2017
Revenue
$19.83Mn
Net Profits
$-15.77Mn
Net Profit Margins
-79.55%

Highlights

Revenue:

AVADEL PHARMACEUTICALS-ADR’s revenue fell -50.03% since last year same period to $19.83Mn in the Q3 2018. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated -32.17% fall in its revenue since last 3-months.

Net Profits:

AVADEL PHARMACEUTICALS-ADR’s net profit fell -172.75% since last year same period to $-15.77Mn in the Q3 2018. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated -358.73% fall in its net profits since last 3-months.

Net Profit Margins:

AVADEL PHARMACEUTICALS-ADR’s net profit margin fell -245.58% since last year same period to -79.55% in the Q3 2018. On a quarterly growth basis, AVADEL PHARMACEUTICALS-ADR has generated -576.31% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the AVADEL PHARMACEUTICALS-ADR post its latest quarter earnings

EPS Estimate Current Quarter
-0.27
EPS Estimate Current Year
-0.27

Highlights

EPS Estimate Current Quarter:

AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) estimates for the current quarter stand at -0.27 - a -1.45% fall from last quarter’s estimates.

EPS Estimate Current Year:

AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) estimates for the current year stand at -0.27.

Key Ratios

Key ratios of the AVADEL PHARMACEUTICALS-ADR post its Q1 2023 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

AVADEL PHARMACEUTICALS-ADR’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the AVADEL PHARMACEUTICALS-ADR has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

202320222021202020192018201720162015
Earnings DateEstimated EPSReported EPSSurprise %
2016-11-14
-0.23
-0.54
-134.78%
2016-04-29
0.14
-0.15
-207.14%
2017-03-28
-0.29
0.11
137.93%
2016-08-15
0.06
-0.48
-900%

Company Information

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Organisation
AVADEL PHARMACEUTICALS-ADR
Headquarters
10 Earlsfort Terrace, Dublin, Ireland, 2
Employees
66
Industry
Health Technology
CEO
Gregory Divis